Proposed Collection; Comment Request (60-Day FRN): The National Cancer Institute (NCI) SmokefreeTXT (Text Message) Program Evaluation (NCI), 2678-2679 [2013-00572]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with
2678
Federal Register / Vol. 78, No. 9 / Monday, January 14, 2013 / Notices
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Kalyani Bhatt, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533, email:
ACRHD@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee link, or call the advisory
committee information line to learn
about possible modifications before
coming to the meeting.
Agenda: On March 5, 2013, the
committees will discuss whether the
benefit of calcitonin salmon for the
treatment of postmenopausal
osteoporosis (thinning and weakening of
bones that increase the chance of having
a broken bone) outweighs a potential
risk of cancer. Calcitonin salmon
products approved for the treatment of
osteoporosis include: Miacalcin
(calcitonin salmon) injection and nasal
spray, submitted by Novartis
Pharmaceuticals Corporation; Fortical
(calcitonin salmon recombinant) nasal
spray, submitted by Upsher Smith
Laboratories; and the generic
equivalents of these products.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 15, 2013.
VerDate Mar<15>2010
16:53 Jan 11, 2013
Jkt 229001
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before February
7, 2013. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 8, 2013.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Kalyani
Bhatt at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 8, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2013–00507 Filed 1–11–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request (60-Day FRN): The National
Cancer Institute (NCI) SmokefreeTXT
(Text Message) Program Evaluation
(NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
SUMMARY:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited to address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To submit comments in writing,
request more information on the
proposed project, or to obtain a copy of
the data collection plans and
instruments, contact: Erik Augustson,
Ph.D., MPH, Behavioral Scientist/Health
Science Administrator, Division of
Cancer Control and Population
Sciences, 6130 Executive Blvd., EPN–
4034, Bethesda, MD 20892–7337 or call
non-toll-free number 301–435–7610 or
Email your request, including your
address to: augustse@mail.nih.gov.
Comments regarding this information
collection are best assured of having
their full effect if received within 60
days of the date of this publication.
Proposed Collection: The National
Cancer Institute (NCI) SmokefreeTXT
Program Evaluation (NCI), 0925–NEW,
National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: This is a request for OMB to
approve the new submission titled,
‘‘The National Cancer Institute (NCI)
SmokefreeTXT Program Evaluation’’ for
3 years. The supporting statements and
various attachments accompany this
memorandum.
This study seeks to assess the efficacy
of the SmokefreeTXT program, a text
message smoking cessation intervention
designed for young adult smokers ages
18–29. The SmokefreeTXT program is a
component of a larger series of eHealth/
mHealth tobacco cessation intervention
programs. SmokefreeTXT has been
developed (and is managed) by the
E:\FR\FM\14JAN1.SGM
14JAN1
2679
Federal Register / Vol. 78, No. 9 / Monday, January 14, 2013 / Notices
National Cancer Institute (NCI) Tobacco
Control Research Branch (TCRB) at the
request of the Office of the Assistant
Secretary for Health (OASH) at the
Department of Health and Human
Services (DHHS).
The study seeks to recruit a large
sample of young adult smokers ages 18–
29 to examine how exposure to the
SmokefreeTXT intervention affects
participants’ success at quitting
smoking. There will be 3-arms to the
study; participants will be enrolled for
total of 7,136 burden hours: (1) Pretreatment baseline survey; (2) one week
post quit date questionnaire; (3) end of
active cessation treatment
questionnaire; (4) 12-week posttreatment questionnaire; (5) 24-weeks
post-treatment questionnaire.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
8,353.
a maximum of 8 weeks of treatment in
the SmokefreeTXT program, with
frequency and duration of the treatment
varying by study arm. The
SmokefreeTXT Study will collect selfreported cessation data using the
bidirectional aspect of text-messaging
service and a series of web-based
surveys. All web-based survey data will
be collected and stored by a third-party,
Research Triangle Institute International
(RTI). Respondents will complete the
following 5 web-based surveys for a
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average time
per response
(in hours)
Total burden
hours
Type of respondents
Survey instrument
Young Adults ......................
Screener/recruitment .......................................
Baseline ..........................................................
1 week post-quit date .....................................
6 weeks post quit date ....................................
12 weeks post-treatment ................................
24 weeks post treatment ................................
Exit Survey/Script ............................................
21,000
4,248
3,399
2,721
2,178
1,308
16,752
1
1
1
1
1
1
1
5/60
30/60
15/60
30/60
15/60
15/60
5/60
1,750
2,124
850
1,361
545
327
1,396
Total ................................................................
........................
........................
........................
8,353
Dated: January 8, 2013.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, NCI, NIH.
[FR Doc. 2013–00572 Filed 1–11–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Vector Biology Study Section
Date: February 6, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
16:53 Jan 11, 2013
Jkt 229001
Place: Sheraton DFW Airport, 4440 W.
John Carpenter Frwy., Irving, TX 75063.
Contact Person: Liangbiao Zheng, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3214,
MSC 7808, Bethesda, MD 20892, 301–402–
5671, zhengli@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR:
Selected Topics in Transfusion Medicine.
Date: February 6–7, 2013.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Bukhtiar H. Shah, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120,
MSC 7802, Bethesda, MD 20892, 301–806–
7314, shahb@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Synapses, Cytoskeleton and
Trafficking Study Section.
Date: February 7–8, 2013.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: InterContinental Chicago Hotel, 505
North Michigan Avenue, Chicago, IL 60611.
Contact Person: Jonathan K. Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4186,
MSC 7850, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Molecular Oncogenesis Study Section.
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Date: February 11–12, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Nikko San Francisco, 222
Mason Street, San Francisco, CA 94102.
Contact Person: Nywana Sizemore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804, Bethesda, MD 20892, 301–435–
1718, sizemoren@csr.nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group;
Hepatobiliary Pathophysiology Study
Section.
Date: February 11–12, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Bonnie L. Burgess-Beusse,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, 301–435–
1783, beusseb@mail.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Adult Psychopathology and Disorders
of Aging Study Section.
Date: February 11–12, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crystal Gateway Marriott, 1700
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Serena Chu, Ph.D.,
Scientific Review Officer, BBBP IRG, Center
for Scientific Review, National Institutes of
E:\FR\FM\14JAN1.SGM
14JAN1
]]>Agencies
[Federal Register Volume 78, Number 9 (Monday, January 14, 2013)]
[Notices]
[Pages 2678-2679]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00572]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request (60-Day FRN): The National
Cancer Institute (NCI) SmokefreeTXT (Text Message) Program Evaluation
(NCI)
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Institutes of Health
(NIH) will publish periodic summaries of proposed projects to be
submitted to the Office of Management and Budget (OMB) for review and
approval.
Written comments and/or suggestions from the public and affected
agencies are invited to address one or more of the following points:
(1) Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) The quality, utility, and clarity of the information to be
collected; and (4) Minimize the burden of the collection of information
on those who are to respond, including the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology.
To submit comments in writing, request more information on the
proposed project, or to obtain a copy of the data collection plans and
instruments, contact: Erik Augustson, Ph.D., MPH, Behavioral Scientist/
Health Science Administrator, Division of Cancer Control and Population
Sciences, 6130 Executive Blvd., EPN-4034, Bethesda, MD 20892-7337 or
call non-toll-free number 301-435-7610 or Email your request, including
your address to: augustse@mail.nih.gov.
Comments regarding this information collection are best assured of
having their full effect if received within 60 days of the date of this
publication.
Proposed Collection: The National Cancer Institute (NCI)
SmokefreeTXT Program Evaluation (NCI), 0925-NEW, National Cancer
Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: This is a request for OMB
to approve the new submission titled, ``The National Cancer Institute
(NCI) SmokefreeTXT Program Evaluation'' for 3 years. The supporting
statements and various attachments accompany this memorandum.
This study seeks to assess the efficacy of the SmokefreeTXT
program, a text message smoking cessation intervention designed for
young adult smokers ages 18-29. The SmokefreeTXT program is a component
of a larger series of eHealth/mHealth tobacco cessation intervention
programs. SmokefreeTXT has been developed (and is managed) by the
[[Page 2679]]
National Cancer Institute (NCI) Tobacco Control Research Branch (TCRB)
at the request of the Office of the Assistant Secretary for Health
(OASH) at the Department of Health and Human Services (DHHS).
The study seeks to recruit a large sample of young adult smokers
ages 18-29 to examine how exposure to the SmokefreeTXT intervention
affects participants' success at quitting smoking. There will be 3-arms
to the study; participants will be enrolled for a maximum of 8 weeks of
treatment in the SmokefreeTXT program, with frequency and duration of
the treatment varying by study arm. The SmokefreeTXT Study will collect
self-reported cessation data using the bidirectional aspect of text-
messaging service and a series of web-based surveys. All web-based
survey data will be collected and stored by a third-party, Research
Triangle Institute International (RTI). Respondents will complete the
following 5 web-based surveys for a total of 7,136 burden hours: (1)
Pre-treatment baseline survey; (2) one week post quit date
questionnaire; (3) end of active cessation treatment questionnaire; (4)
12-week post-treatment questionnaire; (5) 24-weeks post-treatment
questionnaire.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 8,353.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondents Survey instrument Number of responses per per response Total burden
respondents respondent (in hours) hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Young Adults................................... Screener/recruitment................... 21,000 1 5/60 1,750
Baseline............................... 4,248 1 30/60 2,124
1 week post-quit date.................. 3,399 1 15/60 850
6 weeks post quit date................. 2,721 1 30/60 1,361
12 weeks post-treatment................ 2,178 1 15/60 545
24 weeks post treatment................ 1,308 1 15/60 327
Exit Survey/Script..................... 16,752 1 5/60 1,396
---------------------------------------------------------------
Total.................................. .............. .............. .............. 8,353
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: January 8, 2013.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, NCI, NIH.
[FR Doc. 2013-00572 Filed 1-11-13; 8:45 am]
BILLING CODE 4140-01-P
